期刊文献+

胞内分枝杆菌临床分离株对大环内酯类和利奈唑胺的药物敏感性研究

Macrolide and Linezolid Susceptibility Testing for Mycobacterium intracellulare Isolates
下载PDF
导出
摘要 目的研究胞内分枝杆菌对克拉霉素、阿奇霉素和利奈唑胺的敏感性,以初步评价其用于胞内分枝杆菌疾病治疗的价值。方法采用微孔板Alamar Blue法测定克拉霉素、阿奇霉素和利奈唑胺对76株胞内分枝杆菌的MIC。结果克拉霉素对胞内分枝杆菌的MIC90为2mg/L,敏感、中介和耐药的比例分别为93.4%(71/76)、0.0%(0/76)和6.6%(5/76);阿奇霉素对胞内分枝杆菌的MIC90为32mg/L,敏感、中介和耐药的比例分别为94.7%(72/76)、0.0%(0/76)和5.3%(4/76);利奈唑胺对胞内分枝杆菌的MIc90为64mg/L,敏感、中介和耐药的比例分别为32.9%(25/76)、22.4%(17/76)和44.7%(34/76)。5株克拉霉素耐药菌株中有4株对阿奇霉素耐药,2株对利奈唑胺耐药。结论胞内分枝杆菌中克拉霉素敏感株占绝大多数,克拉霉素耐药株对阿奇霉素高度交叉耐药,对利奈唑胺部分敏感。 Objective To investigate the susceptibility ofMycobacterium intracellulare isolates to clarithromycin, azithromycin and linezolid, and therefore to explore the possibility of using these drugs to treat Mycobacterium intracellulare diseases. Methods The minimal inhibitory concentrations (MICs) of the 3 antibiotics against 76 Mycobacterium intracellulare isolates were determined by using microplate alamar blue assay (MABA). Results The MIC90 of clarithromycin against Mycobacterium intracellulare isolates was 2 mg/L. The proportion of susceptible, intermediate and resistant isolates to clarithromycin was 93.4% (71/76), 0.0% (0/76) and 6.6% (5/76), respectively.The MIC90 of azithromycin against the isolates was 32 mg/L.The proportion of susceptible, intermediate and resistant isolates to azithromyein was 94.7% (72/76), 0.0% (0/76) and 5.3% (4/76), respectively. The MIC90 of linezolid was 64 mg/L.The proportion of susceptible, intermediate and resistant isolates to linezolid was 32.9 % (25/76), 22.4% (17/76)and 44.7% (34/76), respectively.Among the 5 isolates resistant to clarithromycin, 4 were resistant to azithromycin, and 2 were resistant to linezolid. Conclusions Most of the Mycobacterium intracellulare isolates were sensitive to clarithromycin.High cross-resistance between clarithromycin and azithromycin was present, but some clarithromycin-resistant isolates were sensitive to linezolid.
出处 《结核病与胸部肿瘤》 2014年第2期75-78,共4页 Tuberculosis and Thoracic Tumor
基金 北京市科技新星计划(2011048) 首都卫生发展科研专项(首发2011-2016-02)
关键词 分枝杆菌 鸟复合 微生物敏感性试验 Mycobacterium avium complex Microbial sensitivity tests
  • 相关文献

参考文献19

  • 1全国结核病流行病学抽样调查技术指导组.第四次全国结核病流行病学抽样调查报告[J].中华结核和呼吸杂志,2002,25(1):3-7. 被引量:1184
  • 2王黎霞,成诗明,陈明亭,赵雁林,张慧,姜世闻,何广学,吕青,杜昕,陈伟,刘小秋,阮云洲,王胜芬,夏愔愔,于兰,李峻,李雪,王宇,无.2010年全国第五次结核病流行病学抽样调查报告[J].中国防痨杂志,2012,34(8):485-508. 被引量:2415
  • 3Koh WJ, leong BH, leon K, et al.Clinical significance of the differentiation between Mycobaeterium avium and Myeobacterium intracellulare in M avium complex lung disease .Chest, 2012, 142 : 1482-1488.
  • 4Griffith DE, Aksarnit T, Brown.Elliott BA, et al.An official ATS/IDSA statement : diagnosis, treatment, and prevention of nontu berculous mycobacterial diseases. Am J Respir Crit CareMed, 2007, 175 : 367-416.
  • 5无,唐神结.非结核分枝杆菌病诊断与治疗专家共识[J].中华结核和呼吸杂志,2012,35(8):572-580. 被引量:357
  • 6Clinical and Laboratory Standards Institute.Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes j approved standard M24-A2.2nd ed.Wayne : CLSI, 2011.
  • 7段鸿飞,土井教生,李琦,马屿,陈效友,傅瑜.鸟分枝杆菌复合群对16种抗感染药物药敏试验的分析[J].中华结核和呼吸杂志,2010,33(5):359-362. 被引量:9
  • 8Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am, 2011, 95 : 761-791.
  • 9Shafran SD, Singer J, Zarowny DP, et al.m comparison of two regimens for the treatment of Mycobaeterium avium complex bacteremia in AIDS : rifabutin, ethambutol, andclarithromycinversusrifampin, ethambutol, clofazimine, and ciprofloxaein.Canadian HIV Trials Network Protocol 010 Study Group.N Engl J Med.1996, 335:377-383.
  • 10Heifets LB, Lindholm-Levy P J, Comstock RD.Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacteriam avium. AmRevRespirDis, 1992, 145(4Pt1):856-858.

二级参考文献52

  • 1全国结核病流行病学抽样调查领导小组.1979年全国结核病流行病学抽样调查综合报告[J].中国防痨通讯,1982,2:3-6.
  • 2Koh WJ,Kwon OJ,Jeon K,et al.Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea.Chest,2006,129:341-348.
  • 3Griffith DE,Aksamit T,Brown-Elliott BA,et al.An official ATS/IDSA statement:diagnosis,treatment,and prevention of nontuberculous mycobacterial diseases.Am J Respir Crit Care Med,2007,175:367-416.
  • 4坂谷光則,倉岛篤行,佐藤滋樹,他.肺非结核性抗酸菌症の診断と治療.呼吸,2005,24:106-117.
  • 5Management of opportunist mycobacterial infections:Joint Tuberculosis Committee Guidelines 1999.Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.Thorax,2000,55:210-218.
  • 6McGrath EE,McCabe J,Anderson PB,et al.Guidelines on the diagnosis and treatment of pulmonary non-tuberculous mycobacteria infection.Int J Clin Pract,2008,62:1947-1955.
  • 7Griffith DE,Brown-Elliott BA,Langsjoen B,et al.Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.Am J Respir Grit Care Med,2006,174:928-934.
  • 8Bermudez LE,Inderlied CB,Kolonoski P,et al.Activity of moxifloxacin by itself and in combination with ethambutol,rifabutin,and azithromycin in vitro and in vivo against Mycobacterium avium.Antimicrob Agents Chemother,2001,45:217-222.
  • 9Kohno Y,Ohno H,Miyazaki Y,et al.In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.Antimicrob Agents Chemother,2007,51:4071-4076.
  • 10Fung-Tomc J,Minassian B,Kolek B,et al.In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone,gatifloxacin.J Antimicrob Chemother,2000,45:437-446.

共引文献3881

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部